Inspiration meets innovation at Brandweek, the ultimate marketing experience. Join industry luminaries, rising talent and strategic experts in Phoenix, Arizona this September 23–26 to assess challenges, develop solutions and create new pathways for growth. Register early to save.
NEW YORK Merkley + Partners has joined Abbott Laboratories’ roster of agencies with responsibility for creative duties on three anti-cholesterol drugs, sources said.
Sources identified the drugs as Simcor, Niaspan and Trilipix. Merkley is said to have landed the business after a review. Annual account billings are estimated at $70 million.
It was not immediately clear who the incumbent was. The Omnicom Group agency did not return calls. Abbott declined to comment, saying through a representative that “it’s not Abbott’s practice to comment on our marketing strategies, vendors or potential vendors.”
Past major media spending behind the drugs has been modest.
WORK SMARTER - LEARN, GROW AND BE INSPIRED.
Subscribe today!
To Read the Full Story Become an Adweek+ Subscriber
Already a member? Sign in